Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel.

Itay LotanAdi Wilf-YarkoniYitzhak FriedmanHadas Stiebel-KalishIsrael SteinerMark A Hellmann

Published in: European journal of neurology (2021)

This survey indicates an overall favorable safety profile of the BNT162b2 vaccine in people with MS. These data should be confirmed in further prospective, large-scale studies.

Keyphrases

multiple sclerosis
mass spectrometry
ms ms
coronavirus disease
sars cov
white matter
electronic health record
big data
deep learning